What Гисманал treats: main uses and benefits

The therapeutic use of Гисманал (Astemizole) is relevant for easing symptoms related to heightened physiological activity across common allergic conditions. The active ingredient was commonly used to help manage symptoms linked to seasonal allergic rhinitis and chronic idiopathic urticaria.

---

Control of Chronic Allergic Skin Manifestations

This domain is commonly used to help with conditions characterized by periods of heightened symptoms such as chronic urticaria (hives) and wealing disorders. The medication helps address symptom clusters that may become intense or disruptive, such as systemic itching (pruritus) and the recurrent presentation of raised patches or weals. This supportive function contributes to easing the overall symptom load and helps with the challenges of these disruptive, long-term manifestations.

“The key role of this therapeutic support may assist with managing sustained symptomatic manifestations for both persistent skin wealing and acute seasonal distress.”

Relief of Seasonal and Perennial Allergic Rhinitis

Гисманал is applied across domains where additional symptomatic support is needed, primarily seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis (year-round allergies). It is relevant for easing the typical symptoms related to physical discomfort, specifically persistent sneezing, runny nose (rhinorrhea), and intense eye itching associated with allergic conjunctivitis. This symptomatic support supports general well-being and assists with maintaining functional stability when symptoms interfere with daily functioning during periods of increased discomfort.

---

Quick Facts

Property	Description
Quick Fact:	Supports Management for Systemic Itching
Symptom Scope	Sneezing, Runny Nose, Pruritus, Hives
Use Context	Seasonal and Chronic Management

Regulatory References

1. US Food and Drug Administration (FDA) approval record

Eligibility Map: Who Can and Cannot Use Гисманал (Astemizole) — Official Regulatory Information

This map details the population eligibility and non-eligibility rules for Astemizole, strictly based on government regulatory documentation.

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Established for use in adults and children aged 12 years and above
Populations for whom use is not recommended (if applicable):	Not recommended for use during breastfeeding, as it is not known whether astemizole passes into breast milk
Populations for whom use is contraindicated:	Patients with hepatic dysfunction (liver disease) and those with known hypersensitivity to astemizole
Age-related eligibility rules:	Use in children under 12 years of age is restricted or requires specific caution/monitoring. Geriatric use may require special monitoring due to age-related organ issues.
Condition-specific eligibility rules:	Use is restricted or must be avoided in patients with heart disease, especially an irregular heartbeat. Must be avoided in patients with low potassium levels in their blood (hypokalemia).
Pregnancy and lactation eligibility status (if explicitly documented):	Pregnancy Category C (FDA): Risk to the fetus cannot be ruled out. Use only if potential benefit justifies potential risk.
Eligibility-related restrictions:	Must not be taken with grapefruit or grapefruit juice, as these increase astemizole exposure and the risk of dangerous cardiac side effects.

---

Official Eligibility Statements

• Гисманал is contraindicated in patients with hepatic dysfunction and those with known hypersensitivity to the medicine.
• Use is restricted or must be avoided in individuals with heart disease or low blood potassium (hypokalemia) due to the risk of serious cardiac events.
• The medicine is established for use in adults and children 12 years of age and older.
• Use during pregnancy is classified as Category C by the FDA.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Astemizole primarily by its absolute prohibition in populations with impaired drug metabolism (hepatic dysfunction) and its strict avoidance in populations with pre-existing cardiac or electrolyte risk factors (heart disease, hypokalemia). This structure establishes non-eligibility criteria where the risk of drug-induced QTc prolongation is highest, and it restricts use to those patients 12 years and older who do not possess these documented high-risk characteristics.

Interactions with other medicines and products

Co-administration of astemizole (Гисманал) with certain medicinal products is formally contraindicated due to documented drug–drug pharmacokinetic interactions. The primary mechanism involves the inhibition of hepatic metabolism, specifically via the cytochrome P450 3A4 (CYP3A4) enzyme. This inhibition reduces astemizole's clearance, resulting in increased plasma levels and prolonged systemic exposure.

---

Formal Interaction Restrictions

Interaction Type	Prohibited Medicinal Products
Pharmacokinetic	Macrolide Antibiotics (e.g., erythromycin, clarithromycin), Systemic Antifungal Products (e.g., ketoconazole, itraconazole), other potent CYP3A4 inhibitors.
Pharmacodynamic	Specific Antiarrhythmics (e.g., quinidine, sotalol), other substances documented to prolong the QT interval.

---

Interaction-Related Outcomes

Exposure modification resulting from these interactions can lead to a severe pharmacodynamic outcome: an additive risk of QT interval prolongation, which elevates the potential for serious ventricular arrhythmias. Regulatory guidance mandates prohibition of co-administration rather than dose timing or separation rules.

Population and Substance Notes

A drug–food interaction is documented with grapefruit juice, which is stated to increase astemizole plasma concentration. Furthermore, patients with hepatic impairment and elderly patients are noted in regulatory information as having an increased potential for reduced clearance and drug accumulation when interacting substances are co-administered.

Antagonism of Histamine H1-Receptors

This medication works primarily by blocking the activity of the H1-receptor, a key site for the action of the body's naturally released substance, histamine. This antagonism prevents the initiation of the histaminergic signaling pathway, which modifies the resulting physiological responses driven by histamine signaling in peripheral tissues.

---

Inhibition of Cardiac Potassium Channels

A critical part of the drug's mechanism is its interaction with specific potassium ion channels (hERG) in heart muscle cells. This activity inhibits the normal flow of potassium ions required for the electrical balance of the heart, resulting in the prolongation of the cardiac action potential duration. This mechanistic domain matters because it directly influences cardiac electrophysiology and is a key component of the drug's action on the cardiovascular system.

How to Use Гисманал (Astemizole)

The use of Astemizole is governed by specific administration protocols established in technical documentation, ensuring its predictable systemic action. The medicine is manufactured for oral administration in the form of tablets and an aqueous suspension.

Official Dosing and Frequency

Astemizole is dosed once daily across populations, a pattern consistent with its exceptionally long duration of action. The standard labeled dosing regimens are defined by age:

• Adults and Adolescents (12 years): 10 mg daily.
• Children (6–11 years): 5 mg daily.
• Children (2–5 years): 1.25 mg daily.

Administration Timing and Conditions

A central requirement for the proper use of Astemizole is administration on an empty stomach. The dose must be ingested either one hour before or two hours after a meal. It is generally noted that the dose should be taken with a full glass of water, and no food intake is permitted for at least one hour following administration to maintain the intended absorption kinetics.

Procedural Instructions

To ensure the intended release and absorption of the active ingredient, the oral tablets must be swallowed whole and should not be crushed, chewed, or broken. This adherence to the physical form of the dose is a key procedural constraint outlined in prescribing documentation. The duration of use is generally sustained for chronic conditions or across seasonal periods, aligning with the drug’s intended use for ongoing symptomatic management.

Research Evidence / Overview of Studies for Гисманал

The evidence base for Гисманал ( astemizole) comes primarily from Randomized Controlled Trials (RCTs) and meta-analyses that combine data from numerous studies. This research structure was used to explore symptom patterns related to common allergic conditions under study. The findings reported describe group patterns observed under the specific conditions of the study.

---

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

The research exploring how symptoms change over time for allergic rhinitis (hay fever and year-round allergies) involved large patient populations of Adults. Researchers measured outcomes related to physical discomfort by tracking specific symptoms, such as sneezing, runny nose, and intense eye and nose itching. Studies describe changes measured during the study period for these symptoms. However, trials consistently noted that the achievement of full symptomatic action was delayed for several days following the start of therapy. The research base exhibits a lack of consistent data regarding the impact on other symptoms, specifically nasal congestion or blockage.

Evidence for Use in Chronic Allergic Skin Manifestations

Research also explored conditions characterized by fluctuating manifestations, specifically Chronic Urticaria (hives) and Systemic Itching ( Pruritus). These studies primarily focused on Adults and monitored outcomes linked to irritative states, such as measuring the physical size of hives and the intensity of reported itching. Findings describe patterns observed in the studies, including measurements of changes in the manifestation of hives/weals. The research limitations include that data for long-term control beyond one year remains insufficient.

---

Evidence in Specific Patient Groups and Remaining Uncertainty

The predominant part of the research focused on Adults with allergic conditions; consequently, data for groups such as children or the older adult population is limited within the core clinical trial documents.

Research highlights what is known—and what is still uncertain. Follow-up durations were limited in the most rigorous controlled trials, meaning the full scope of long-term functional outcomes is not completely known. Additionally, comparative evidence exploring performance against newer, currently available antihistamines is lacking in the available research base. Research provides context but not individual predictions, and findings generally reflect the populations studied.

Key Studies & References

1. Determination That Astemizole 10-Milligram Tablets Were Withdrawn From Sale for Safety Reasons
2. Appropriate use of second-generation antihistamines (Review discussing long half-life and metabolism context)

Common questions about Гисманал (FAQ)

---

Q: Is the mechanism of action for Гисманал different from other common allergy drugs?

Official pharmacological labeling describes Astemizole as a non-sedating H1-receptor antagonist, which is a mechanism shared by many allergy medicines. However, its action also involves the inhibition of specific potassium ion channels in the heart. This ability to influence cardiac electrical activity is a key distinction noted in regulatory documents.

Q: Can people with liver or kidney impairment safely be prescribed Гисманал?

Official regulatory documents state that the medicine is contraindicated, meaning strictly prohibited, for use in patients with hepatic dysfunction (severe liver disease). This restriction is based on the risk of dangerous drug accumulation. Information regarding the use of the medicine in patients with kidney impairment is not universally detailed as a contraindication in the core regulatory documents.

Q: Are there common side effects, like dry mouth or dizziness, that usually resolve with continued use?

Regulatory data lists common adverse effects such as dry mouth, fatigue, and somnolence (drowsiness). However, the official documents do not provide information on the typical duration of these effects or whether they are specifically expected to lessen or resolve with continued use.

Q: Is Гисманал available over-the-counter or is it prescription-only in my area?

Regulatory history indicates that the active ingredient, Astemizole, was originally marketed as a prescription drug following its approval. Its current access status, whether it remains prescription-only or is available over-the-counter, depends entirely on the specific regulatory classifications within each country’s health authority.

Q: Is there a difference in effect between taking Гисманал in the morning versus the evening?

Official administration instructions specify that the medicine is dosed once daily and must be taken on an empty stomach. The regulatory documents do not specify a difference in efficacy or safety based on taking the single dose in the morning versus taking it in the evening.

Q: What other diseases or conditions might require caution when prescribing Гисманал?

Official regulatory documents require caution or avoidance in patients with conditions such as hepatic dysfunction (liver disease), pre-existing heart disease—especially an irregular heartbeat—and abnormally low potassium levels in their blood (hypokalemia). These restrictions are established to manage the risk of serious cardiac events.

Q: Does alcohol increase the chance of side effects from Гисманал?

Regulatory warnings advise caution against the use of substances that are known to enhance the central nervous system (CNS) effects of the medicine. Alcohol is a CNS depressant, and its use is typically included in general warnings for substances that could potentially increase the effects of the medication.

Q: What is the general advice for missed doses of Гисманал?

General patient guidance for once-daily medication usually describes a standard approach where a missed dose is taken when remembered, provided it is not nearly time for the next scheduled dose. If it is almost time for the next dose, the missed dose should be skipped to avoid taking two doses too closely together.

Q: Is it true that Гисманал has been withdrawn from the market in some countries?

The active ingredient, Astemizole, was indeed voluntarily withdrawn from sale in major markets, including the US (FDA) and EU (EMA). This action was taken due to serious concerns over the risk of cardiac side effects when the medicine was used at higher-than-recommended doses or in combination with other prohibited drugs.

Q: Is there a generic version of Гисманал available for prescription?

Before the brand name was withdrawn in various markets, regulatory authorities had approved generic equivalents of Astemizole. These records of approved generics are maintained by national drug registers.

Q: Can I take other cold or flu medications while using Гисманал?

Regulatory guidance prohibits co-administration with specific classes of medicine, including Macrolide Antibiotics, Systemic Antifungals, and any other medicine that acts as a potent inhibitor of the CYP3A4 enzyme or prolongs the QT interval. The safety status of a specific cold or flu medication depends on whether its active ingredients fall into these prohibited classes.

Q: Is it necessary to stop taking Гисманал before having an allergy skin test?

Official product information generally advises that antihistamines like Гисманал may need to be discontinued for several days before an allergy skin test. This is necessary because the active ingredient could interfere with the skin's reaction to the test antigens, potentially leading to inaccurate results.

Q: Have researchers studied the effect of Гисманал on the ability to drive or operate machinery?

Due to the potential for common side effects such as somnolence (drowsiness) and fatigue, regulatory documents typically contain a warning noting that caution may be necessary when driving or operating machinery. This warning is based on the drug's known adverse reaction profile.

Q: What is the typical appearance (color, shape) of the Гисманал tablet?

The official package inserts and monographs typically contain a detailed physical description of the tablet. This description usually covers the specific shape, color, and any identification markings (like a logo or code) used to ensure correct product identification.

Q: Does Гисманал affect the results of any common laboratory blood tests?

Regulatory documents state that Astemizole, as an antihistamine, may interfere with the results of antigen-based skin tests. However, the official information does not generally note widespread interference with common laboratory blood test values.

Q: Is Гисманал known to interact with HIV/AIDS medications?

Official information contraindicates use with any medicine classified as a potent inhibitor of the CYP3A4 enzyme (a specific liver enzyme). Many HIV/AIDS medications, such as protease inhibitors, fall into this prohibited class due to the high risk of Astemizole accumulating to dangerous levels in the bloodstream.

How to Store and Dispose of Гисманал (Astemizole)

Storage and disposal must strictly follow the official conditions outlined in regulatory documents to ensure product stability and safety.

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature, between 15 C to 30 C (59 F to 86 F).
Protection	Must be protected from moisture and excessive heat.
Container	Keep the medication in its original container.

The medicine must be stored in a location that is out of the reach of children.

Disposal instructions require that any unused or expired Гисманал be discarded strictly according to local regulations. The product should generally not be flushed down the toilet or poured into a drain unless specifically advised by an official medicine take-back program.